Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Epidemiologia
ed eziologia
della psoriasi
Deng Y, Chang C, Lu Q. The Inflammatory Response in Psoriasis: a Comprehensive Review. Clin Rev Allergy
Immunol. 2016;50(3):377-89.
• Non è comune tra gli asiatici e i cinesi ed estremamente rara tra i popoli
sudamericani4,5
• La prevalenza tra gli americani bianchi è del 4,6% e tra gli americani neri dello 0,7%6
1. Farber EM, Nall L. Epidemiology: natural history and genetics. In: Roenigk HH Jr, Maibach HI, eds. Psoriasis. New York: Dekker; 1998. p. 107-57.
2. Parisi R, Griffiths CEM, Ashcroft DM. Systematic review of the incidence and prevalence of psoriasis. Br J Dermatol. 2011;165:35.
3. Schön MP, Boehncke WH. N Engl J Med. 2005352(18):1899-912. Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun.
2010;34:J314-21.
4. Bowcock AM. The genetics of psoriasis and autoimmunity. Annu Rev Genomics Hum Genet. 2005;6:93-122.
5. Kenney J. Psoriasis in the American Black. In: Faber EM, Cox AJ, eds. Psoriasi: Proceedings of an International Symposium on Psoriasis. Stanford, CA: University Press; 1971; p. 450-51.
1. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13(3):450-6.
2. Lonnberg AS, Skov L, Skytthe A, et al. Heritability of psoriasis in a large twin sample. Br J Dermatol. 2013;169:412-6.
1. Primary Care Dermatology Society. Psoriasis Guideline; 2012. Disponibile a questo indirizzo: http://www.pcds.org.uk/clinical-guidance/psoriasis-an-overview. Last accessed: September 2018
2. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13(3):450-6. Gudjonsson JE, Elder JT. Psoriasis:
epidemiology. Clin Dermatol. 2007;25(6):535-46. Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352(18):1899-912.
1. Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet. 2006;78(5):827-51.
2. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-94.
1. Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet. 2006;78(5):827-51.
2. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-94.
• Spesso simmetrica
BMI, body mass index; QoL, quality of life; VAS, Visual Analogue Scale.
Prignano F, Ricceri F, Pescitelli L, et al. Itch in Psoriasis: epidemiology, clinical aspects and treatment options. Clin Cosmet Investig Dermatol. 2009;2:9-13.
Psoriasi intertriginosa
Colpisce principalmente l’area genitale, le ascelle, l'area sottostante il seno (nelle donne),
la caratteristica desquamazione è spesso assente, nettamente demarcata, lesioni rosse
Psoriasi guttata
Lesioni molto piccole, della grandezza di una testa di spillo o di un pisello (spesso
associata a infezione da streptococco)
Psoriasi eritrodermica
Eritema e desquamazione su tutta la superficie cutanea
Psoriasi pustolosa
Presenza di pustole sterili su cute eritematosa in zona palmo-plantare, quando localizzata o
su tutta la superficie cutánea quando generalizzata; dolorosa
Artrite psoriasica
A seconda dell'autore, l’artrite psoriasica può essere considerata una forma clinica
di psoriasi o una comorbidità
Levine D, Gottlieb A. Evaluation and management of psoriasis: an internist's guide. Med Clin North Am. 2009;93(6):1291–303.
Christophers E, Mrowietz U, Sterry W. Psoriasis – auf einen Blick. Blackwell; 2002.
Christophers E, Mrowietz U. Psoriasis. In: Freedberg IM, Eisen AZ, Wolff A, et al. Dermatology in general medicine. 6th ed. New York: McGraw-Hill; 2003. p. 407-27.
Schlager JG, Rosumeck S, Werner RN, et al. Topical treatments for scalp psoriasis: summary of a Cochrane Systematic Review. Br J Dermatol. 2017;176(3);604-14.
1. Boehncke WH, Menter A. Burden of disease: psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2013;14:377-88.
2. Lloyd P, Ryan C, Menter A. Psoriatic arthitis: an update. Arthritis. 2012;2012:176298.
3. Prey S, Paul C, Bronsard V, et al. Assessmrent of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature.
J Eur Acad Dermatol Venereol. 2010;24(2):31-5.
HR 3,89
HR 2,35
HR 2,93
Wilson FC, Icen M, Crowson CS et al. Incidence and clinical predictors of psoriatic arthritis
in patients with psoriasis: a population-based study. Arthr Rheum. 2009;61(2):233-9.
2. Von Kiedrowski et al. Dt Dermatologe. 2013;3.
Bronckers IM, Paller AS, Van Geel MJ et al. Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Paediatr Drugs. 2015;17(5):373-84.
Bronckers IM, Paller AS, Van Geel MJ et al. Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Paediatr Drugs. 2015;17(5):373-84.
• Psoriasi moderata-grave
BSA>10 o PASI>10 o DLQI>10
BSA>10 o PASI>10 o DLQI>10
Mrowietz U, Kragballe K, Reich K et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1-10.
Nast A, Spuls PI, Van der Kraaij G, European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. J Eur Acad
Dermatol Venereol. 2017;31(12):1951-63.
Nast A, Spuls PI, Van der Kraaij G, European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. J Eur Acad
Dermatol Venereol. 2017;31(12):1951-63.
Nast A, Spuls PI, Van der Kraaij G, European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. J Eur Acad
Dermatol Venereol. 2017;31(12):1951-63.
Nast A, Spuls PI, Van der Kraaij G, European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. J Eur Acad
Dermatol Venereol. 2017;31(12):1951-63.
• Diabete di tipo 2
1. Nograles KE, Brasington RD, Bowcock AM. New insights into the pathogenesis and genetics of psoriatic arthritis. Nat Clin Pract Rheumatol. 2009;5:83-91.
2. Dowlatshahi EA, Van der Voort EA, Arends LR et al. Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2013;169:266-82.
3. Davidovici BB, Sattar N, Prinz J, Puig L, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol.
2010;130:1785-96.
Feldman SR, Zhao Y, Shi L, Tran MH. Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis. J Manag Care Spec Pharm. 2015;21:874-88.
Gelfand JM, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296(14):1735-41.
Gelfand JM, Troxel AB, Lewis JD. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143(12):1493-99.
Ludwig RJ, Herzog C, Rostock A et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007;156:271-6.
Gelfand JM, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296(14):1735-41.
Gelfand JM, Troxel AB, Lewis JD. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143(12):1493-99.
Ludwig RJ, Herzog C, Rostock A et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007;156:271-6.
Katsambas A. Treating psoriasis as a chronic inflammatory systemic disease. Br J Dermatol. 2008:159(Suppl. 2):1-17.
Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143:1493-9.